Amgen CTO David Reese to Retire June 30, AI Leadership Overhaul Announced
Amgen executive vice president and chief technology officer David Reese will retire June 30 after leading R&D since 2005, overseeing multiple drug approvals and AI integration. Effective June 1, James Bradner becomes EVP R&D, AI and Data; Sean Bruich is CTO; Murdo Gordon EVP Markets & Policy.
1. Retirement of David Reese
Amgen announced that Dr. David M. Reese, executive vice president and chief technology officer, will retire June 30, 2026, after joining the company in 2005. During his tenure, Reese led approvals of numerous innovative medicines and biosimilars, served as EVP of R&D from 2018 to 2023, and championed early AI adoption across research and development.
2. New Leadership Appointments
Effective June 1, 2026, Amgen names James Bradner, M.D., as executive vice president of Research and Development, Artificial Intelligence and Data, leveraging his physician-scientist expertise in emerging biomedical technologies. Sean Bruich is appointed senior vice president and chief technology officer to advance AI and data capabilities, and Murdo Gordon becomes executive vice president of Markets & Policy, overseeing medical, commercial and government affairs.
3. Strategic Focus on Convergent Innovation
These organizational changes deepen Amgen’s convergent innovation strategy, integrating biology, data science and advanced technologies to accelerate drug discovery and development. By aligning leadership roles around AI, data and global market policy, Amgen aims to strengthen its pipeline execution and expand patient access to new therapies.